Evidence map›Paper›PMID 41157133›Full record

ArticleMolecules (Basel, Switzerland)2025

Factors Driving Amyloid Beta Fibril Recognition by Cell Surface Receptors: A Computational Study.

Olivia Slater, Maria Kontoyianni

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olivia SlaterDepartment of Pharmaceutical Sciences, Southern Illinois University, Edwardsville, IL 62026, USA.ORCID 0000-0002-8821-9570
Maria KontoyianniDepartment of Pharmaceutical Sciences, Southern Illinois University, Edwardsville, IL 62026, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) has been studied extensively and is characterized by plaques deposited throughout the brain. Plaques are made of beta-amyloid (

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesReceptors, Cell SurfaceHumansHydrogen-Ion ConcentrationLipopolysaccharide ReceptorsMutationProtein BindingReceptor for Advanced Glycation End ProductsToll-Like Receptor 2Toll-Like Receptor 4Amyloid beta-PeptidesLipopolysaccharide ReceptorsReceptor for Advanced Glycation End ProductsReceptors, Cell SurfaceTLR2 protein, humanTLR4 protein, humanToll-Like Receptor 2Toll-Like Receptor 4Alzheimer’s diseaseAβ fibrilsbeta-amyloidReceptor for Advanced Glycation End products (RAGE)toll-like receptors

Identifiers

PMID41157133
PMCPMC12566521

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.